An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic Medication

NCT05741528 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

75

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: SEP-363856

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.